[go: up one dir, main page]

MX2019011692A - Nuevo tratamiento de enfermedades mitocondriales. - Google Patents

Nuevo tratamiento de enfermedades mitocondriales.

Info

Publication number
MX2019011692A
MX2019011692A MX2019011692A MX2019011692A MX2019011692A MX 2019011692 A MX2019011692 A MX 2019011692A MX 2019011692 A MX2019011692 A MX 2019011692A MX 2019011692 A MX2019011692 A MX 2019011692A MX 2019011692 A MX2019011692 A MX 2019011692A
Authority
MX
Mexico
Prior art keywords
novel treatment
mitochondrial diseases
treatment
mitochondrial
diseases
Prior art date
Application number
MX2019011692A
Other languages
English (en)
Inventor
David BEYRATH Julien
Albertus Maria Smeitink Johannes
Original Assignee
Khondrion Ip B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58489616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019011692(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Khondrion Ip B V filed Critical Khondrion Ip B V
Publication of MX2019011692A publication Critical patent/MX2019011692A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un tratamiento innovador para los trastornos mitocondriales y las enfermedades o afecciones asociadas con la disfunción mitocondrial. En particular, se han establecido dosis efectivas y seguras de compuestos adecuados para el tratamiento de trastornos mitocondriales, que se proporcionan para nuevos regímenes de tratamiento y poblaciones de pacientes.
MX2019011692A 2017-04-05 2017-09-05 Nuevo tratamiento de enfermedades mitocondriales. MX2019011692A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17165012 2017-04-05
PCT/EP2017/072172 WO2018184706A1 (en) 2017-04-05 2017-09-05 Novel treatment of mitochondrial diseases

Publications (1)

Publication Number Publication Date
MX2019011692A true MX2019011692A (es) 2020-02-10

Family

ID=58489616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011692A MX2019011692A (es) 2017-04-05 2017-09-05 Nuevo tratamiento de enfermedades mitocondriales.

Country Status (8)

Country Link
US (3) US11285130B2 (es)
EP (2) EP3606522B1 (es)
KR (1) KR102660473B1 (es)
AU (1) AU2017408066B2 (es)
CA (1) CA3058033A1 (es)
ES (1) ES2959243T3 (es)
MX (1) MX2019011692A (es)
WO (1) WO2018184706A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202003743SA (en) * 2017-11-22 2020-06-29 Khondrion Ip B V Compounds as mpges-1 inhibitors
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure
NL2031091B1 (en) * 2022-02-28 2023-09-07 Sulfateq Bv Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders
WO2025030121A1 (en) * 2023-08-02 2025-02-06 Calico Life Sciences Llc Biomarkers of the integrated stress response and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204232D0 (en) 2002-02-22 2002-04-10 Isis Innovation Assay
US7968746B2 (en) * 2007-11-06 2011-06-28 Edison Pharmaceuticals, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
JP2013538799A (ja) 2010-08-06 2013-10-17 アンペア ライフ サイエンシーズ，インコーポレイテッド ビタミンｋを用いたミトコンドリア病の処置
US20130345312A1 (en) 2010-08-06 2013-12-26 Orion D. Jankowski Treatment of mitochondrial diseases with naphthoquinones
MX364547B (es) * 2012-07-12 2019-04-30 Khondrion Ip B V Derivados de cromanil para tratar enfermedad mitocondrial.
SI2872497T2 (sl) 2012-07-12 2019-12-31 Khondrion Ip B.V. Derivati kromanila za zdravljenje mitohondrijske bolezni
NL2010010C2 (en) 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
ES3033538T3 (en) * 2015-10-08 2025-08-05 Khondrion Ip B V Novel compounds for treating mitochondrial disease
SG11202003743SA (en) * 2017-11-22 2020-06-29 Khondrion Ip B V Compounds as mpges-1 inhibitors
ES3020732T3 (en) * 2017-11-22 2025-05-23 Khondrion Ip B V Amide derivatives of chromanyl or chromanyl quinones for use in treating depression and migraine

Also Published As

Publication number Publication date
EP3606522A1 (en) 2020-02-12
US12226394B2 (en) 2025-02-18
KR20190133206A (ko) 2019-12-02
EP3606522C0 (en) 2023-07-12
US11285130B2 (en) 2022-03-29
US20210113520A1 (en) 2021-04-22
AU2017408066B2 (en) 2023-08-24
KR102660473B1 (ko) 2024-04-24
WO2018184706A1 (en) 2018-10-11
ES2959243T3 (es) 2024-02-22
AU2017408066A1 (en) 2019-11-21
EP3606522B1 (en) 2023-07-12
AU2017408066A2 (en) 2019-11-21
EP4241842A2 (en) 2023-09-13
US20240390321A1 (en) 2024-11-28
US20220265604A1 (en) 2022-08-25
EP4241842A3 (en) 2023-11-08
CA3058033A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
MX2021009830A (es) Metodos para el tratamiento de trastornos del movimiento involuntario anormal.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
MY187540A (en) Compounds active towards bromodomains
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
GB2541571A (en) Pharmaceutical compositions
RS67082B1 (sr) Kombinacije aprocitentana sa drugim aktivnim sastojcima za lečenje rezistentne hipertenzije
PH12017501990A1 (en) Imidazopyrazinones as pde1 inhibitors
MX2017002489A (es) Agentes terapeuticos humanos.
WO2016077639A3 (en) Nanovesicular therapies
PH12020550255A1 (en) Treatment of smc mediated disease
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
MX379201B (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX378607B (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2017014782A (es) Metodo para el tratamiento de enfermedad neurologica.
MX2019011692A (es) Nuevo tratamiento de enfermedades mitocondriales.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
TW201713323A (en) Therapeutic compositions and methods of use thereof
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.